Benitec develops gene therapies for rare genetic diseases, led by a treatment candidate for oculopharyngeal muscular dystrophy. BNTC reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 23 | Raymond James | Initiated | Buy | |
| Sep 15 | Wedbush | Target raised | Buy | |
| Jul 28 | Wedbush | Initiated | Buy | |
| May 12 | Evercore ISI Group | Initiated | Buy |
Seasonality
How BNTC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in BNTC in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTC is in one of them and how their past BNTC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BNTC in an article yet. Here's the latest on the wider market.
About Benitec Biopharma
Benitec is a biotechnology company in Hayward, California, that develops genetic medicines for rare diseases. Its lead product candidate, BB-301, is a gene therapy being tested for oculopharyngeal muscular dystrophy, a degenerative muscle disorder that affects swallowing, eyelids and limbs. The company's approach uses viral vectors to deliver genetic material that silences a harmful gene while replacing it with a working copy. Its intended users are patients with this condition, and it may work with larger drug companies on some programs.
- Headquarters
- Hayward, CA